|
rs2010963
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genomic DNA was isolated from whole blood for the analysis of <i>VEGF-A</i> (rs2010963, 1570360, rs699947), <i>ICAM-1</i> (rs5498, rs1799969) SNPs and from tumor tissue for the detection of genomic variants in <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> genes.
|
31752122 |
2019 |
|
rs699947
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genomic DNA was isolated from whole blood for the analysis of <i>VEGF-A</i> (rs2010963, 1570360, rs699947), <i>ICAM-1</i> (rs5498, rs1799969) SNPs and from tumor tissue for the detection of genomic variants in <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> genes.
|
31752122 |
2019 |
|
rs699947
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Variant genotypes of rs699947 (CA + AA) were significantly associated with high-grade (G2 + G3) tumors (OR = 1.82; 95% CI = 1.15 - 2.89), and with shorter disease-free survival among patients treated with neoadjuvant chemotherapy followed by mastectomy (HRadjusted = 1.82; 95% CI = 1.16 - 2.86).
|
27195611 |
2016 |
|
rs833061
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Variant genotypes of rs833061 (TC + CC) were significantly associated with high-grade (G2 + G3) tumors (OR = 1.79; 95% CI = 1.12 - 2.84) and with positive lymph node status (OR = 1.34; 95% CI = 1.01 - 1.77), but showed no independent effect on disease-free survival.
|
27195611 |
2016 |
|
rs833061
|
|
|
0.030 |
GeneticVariation |
BEFREE |
However, when the patients were stratified by tumor histology, squamous cell carcinoma (SCC) and adenocarcinoma (AC) had significantly different OS (Adjusted hazard ratio [aHR] = 0.76, 95% CI = 0.56-1.03 in SCC; aHR = 1.33, 95% CI = 0.98-1.82 in AC; P for heterogeneity = 0.01) and DFS (aHR = 0.75, 95% CI = 0.58-0.97 in SCC; aHR = 1.26, 95% CI = 1.00-1.60 in AC; P for heterogeneity = 0.004) according to the rs833061T>C genotypes.
|
27709850 |
2016 |
|
rs2010963
|
|
|
0.030 |
GeneticVariation |
BEFREE |
After stratifying by tumor molecular subtype, SNP associations observed for colon cancer were: VEGFA rs2010963 with CIMP+ colon tumors; FLT1 rs4771249 and rs7987649 with TP53; FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.
|
23794399 |
2014 |
|
rs2010963
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Blood and tumor tissue from 83 patients with NSCLC were examined for VEGF -460T/C (rs833061) and VEGF +405G/C (rs2010963) SNPs using the SNaPshot method.
|
23064377 |
2013 |
|
rs833061
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Blood and tumor tissue from 83 patients with NSCLC were examined for VEGF -460T/C (rs833061) and VEGF +405G/C (rs2010963) SNPs using the SNaPshot method.
|
23064377 |
2013 |
|
rs699947
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our results seem to indicate that combining information from genotyping of rs699947 (VEGFA, AC), rs2269772 (ITGA, AA) and tumour histology could allow clinicians to individuate gastric cancer at high risk for recurrence either with peritoneal or hematogenous metastases.
|
22808003 |
2012 |
|
rs1443465532
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Treatment of SK-BR-3 breast cancer xenografts with anti-HER2 IgG3-huEndo-P125A fusion resulted in greater inhibition of tumor growth and improved survival, compared to treatment with either αHER2 IgG3 (P = 0.025), human endostatin (P = 0.034), or anti-HER2 IgG3-huEndo (P = 0.016).
|
21393427 |
2011 |
|
rs1443465532
|
|
|
0.030 |
GeneticVariation |
BEFREE |
P125A-endostatin also localised into tumour tissue to a higher degree than the native protein, and displayed greater inhibition of growth of colon cancer in athymic mice.
|
15083196 |
2004 |
|
rs1443465532
|
|
|
0.030 |
GeneticVariation |
BEFREE |
CD-31 (platelet-endothelial cell adhesion molecule [PECAM]) staining revealed that blood vessels developed in tumors larger than 1 mm The administration of P125A human endostatin in C3(1)/Tag females resulted in a significant delay in tumor onset, decreased tumor multiplicity and tumor burden and prolonged survival of the animals.
|
12209972 |
2002 |
|
rs1201894677
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggested that K20E suppressed the tumor growth in the allograft tumor model and exhibited anti-angiogenic activity in Matrigel plug assay.
|
25481497 |
2015 |
|
rs1201894677
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The AKT1 (E17K) mutation in the tumor was not detectable in all investigated specimens.
|
26077595 |
2015 |
|
rs140461341
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Tumor-associated macrophages in surgical specimens and sensitivity to CSF-1R inhibitors were used to determine macrophage function.<b>Results:</b> A <i>CSF1R</i> c.1085A>G genetic variant causing the change of histidine to arginine in the domain of receptor dimerization was identified as a high allele frequency in Eastern Asian population.
|
28724665 |
2017 |
|
rs1421145908
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results suggested that K20E suppressed the tumor growth in the allograft tumor model and exhibited anti-angiogenic activity in Matrigel plug assay.
|
25481497 |
2015 |
|
rs914956206
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression.
|
25359494 |
2015 |
|
rs748984440
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A fusion protein composed of human vascular endothelial growth factor (VEGF) and staphylococcal enterotoxin A (SEA) with a D227A mutation strongly repressed the growth of murine solid sarcoma 180 (S180) tumors (control versus VEGF-SEA treated with 15μg, mean tumor weight: 1.128g versus 0.252g, difference=0.876g).
|
23036194 |
2012 |
|
rs1222213359
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The GA+AA genotypes of -1154G/A were weakly associated with smaller tumors, lower tumor stage, and lower stage grouping (p=0.028, p=0.012, and p=0.028, respectively).
|
17287073 |
2007 |
|
rs1284410244
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To directly assess its role in tumor growth and metastasis in vivo, we stably transfected HT-1080 fibrosarcoma cells expressing either fully active wild-type human TFPI-2 (WT) or inactive R24Q TFPI-2 (QT) and examined their ability to form tumors and metastasize in athymic mice in comparison to mock-transfected cells (MT).
|
14525759 |
2004 |
|
rs541717889
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Despite the late take, the VEGF-Cys51Ser and VEGF-Cys60Ser tumors developed an extensive vascular bed with an architecture comparable to that of recombinant wtVEGF-producing tumors whereas control tumors had a considerably lower vascular density.
|
11169955 |
2001 |